Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
ADC Therapeutics $204 million SEC-registered offering
Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross…
Zai Lab HK$5.94 billion secondary listing and IPO on the HKEX
Davis Polk advised Zai Lab Limited in connection with its secondary listing and initial public offering on the Hong Kong…
GoodRx Holdings $1.3 billion IPO
Davis Polk advised the representatives of the several underwriters in connection with the $1.3 billion initial public…
Omnicell $575 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in a Rule 144A offering by Omnicell, Inc. of $575 million…
Humanigen stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with…
American Well $853 million IPO and NYSE listing
Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares…
Natera $287.5 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with the follow-on offering of 4,791…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…
MDLIVE $50 million private placement
Davis Polk advised MDLIVE Inc. in connection with its private placement of approximately $50 million in shares of its Series…
Venus Medtech (Hangzhou) HK$1.2 billion H shares placement
Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its placing of 18,500,000 new H shares for an aggregate…